A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCC)

被引：0
作者：
Cen, P. [1 ]
Daleiden, A. [1 ]
Doshi, G. [1 ]
Amato, R. [1 ]
机构：
[1] Univ Texas Houston, Sch Med, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16056
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Dang, Long H.
    Lauer, Richard C.
    Starodub, Alexander
    Hauke, Ralph J.
    Galsky, Matt D.
    Bylow, Kathryn A.
    Cowey, Charles Lance
    Bibby, David C.
    Kremmidiotis, Gabriel
    Doolin, Elizabeth E.
    Lavranos, Tina C.
    Sonpavde, Guru
    Logan, Theodore
    Hahn, Noah M.
    Sweeney, Christopher
    Sarantopoulos, John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [12] Phase 1 Trial of Everolimus Plus Sunitinib in Patients With Metastatic Renal Cell Carcinoma
    Molina, Ana M.
    Feldman, Darren R.
    Voss, Martin H.
    Ginsberg, Michelle S.
    Baum, Michael S.
    Brocks, Dion R.
    Fischer, Patricia M.
    Trinos, Michael J.
    Patil, Sujata
    Motzer, Robert J.
    CANCER, 2012, 118 (07) : 1868 - 1876
  • [13] Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Gordon, M. S.
    Stein, M.
    Shannon, P.
    Eddy, S.
    Tyler, A.
    Catlett, L.
    Hsyu, P.
    Huang, B.
    Healey, D.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [14] Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma
    Kroog, G. S.
    Feldman, D. R.
    Kondagunta, G. V.
    Ginsberg, M. S.
    Fischer, P. M.
    Trinos, M. J.
    Patil, S.
    Ishill, N. M.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [15] Phase I study of IMP321 in metastatic renal cell carcinoma (MRCC)
    Escudier, Bernard
    Brignone, Chrystelle
    Grygar, Caroline
    Marcu, Manon
    Triebel, Frederic
    JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 885 - 885
  • [16] PHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M.
    Rini, B. I.
    McDermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M.
    Sharma, P.
    Kollmannsberger, C. K.
    Heng, D.
    Shen, Y.
    Kurland, J.
    Spratlin, J.
    Gagnier, P.
    Amin, A.
    ANNALS OF ONCOLOGY, 2014, 25
  • [17] Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Ernstoff, Marc S.
    Rini, Brian I.
    McDermott, David F.
    Razak, Albiruni R. A.
    Pal, Sumanta Kumar
    Voss, Martin Henner
    Sharma, Padmanee
    Kollmannsberger, Christian K.
    Heng, Daniel Yick Chin
    Spratlin, Jennifer L.
    Shen, Yun
    Kurland, John F.
    Gagnier, Paul
    Amin, Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [18] Comorbidity and sorafenib (SOR) therapy in elderly patients with metastatic renal cell carcinoma (mRCC)
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [19] SUNITINIB AND SORAFENIB THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC): SAFETY PROFILE
    Massari, Francesco
    Cricca, Antonia
    Sperandi, Francesca
    Martoni, Andrea Angelo
    ANTICANCER RESEARCH, 2010, 30 (04) : 1379 - 1380
  • [20] Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC)
    Osanto, S.
    Hutson, T. E.
    Calvo, E.
    Escudier, B. J.
    Oudard, S.
    Porta, C.
    Bracarda, S.
    Grunwald, V.
    Ravaud, A.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345